Get the Stockscreener App
24.55
1.72%
-0.43
After Hours:
24.55
Anaptysbio Inc stock is traded at $24.55, with a volume of 507.35K.
It is down -1.72% in the last 24 hours and up +10.59% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$24.98
Open:
$25.255
24h Volume:
507.35K
Relative Volume:
0.91
Market Cap:
$721.29M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-4.0378
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-9.04%
1M Performance:
+10.59%
6M Performance:
+36.92%
1Y Performance:
-29.54%
1-Day Range:
$24.39
$25.25
1-Week Range:
$23.61
$27.47
52-Week Range:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
24.55 | 733.92M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
What makes AnaptysBio Inc. stock price move sharplyBest Dividend Picks For 2025 - jammulinksnews.com
What catalysts could drive AnaptysBio Inc. stock higher in 2025Retirement Planning Tracker To Watch Now - jammulinksnews.com
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Here's Why - MarketBeat
How does AnaptysBio Inc. compare to its industry peersFinancial News Updates For Consistent Profits - jammulinksnews.com
Is it the right time to buy AnaptysBio Inc. stockDaily Trading Strategy For Smart Trading - jammulinksnews.com
Skandinaviska Enskilda Banken AB publ Takes $623,000 Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc. Moves Into Bullish Territory Based on MACDValue Investing Picks With Stability Outlined - metal.it
Victory Capital Management Inc. Has $7.56 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Why is AnaptysBio Inc. stock attracting strong analyst attentionWealth Building Trend Scanner For Smart Trading - jammulinksnews.com
How does AnaptysBio Inc. generate profit in a changing economyEarnings Report Outlook For 2025 - jammulinksnews.com
What is the risk reward ratio of investing in AnaptysBio Inc. stockMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
What are AnaptysBio Inc. company’s key revenue driversChart Pattern Updates With High Returns - jammulinksnews.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corton Capital Inc. Acquires Shares of 10,699 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
What technical models suggest about AnaptysBio Inc.’s comebackAI Screener for Daily Stock Forecast - Newser
AnaptysBio (ANAB) Projected to Post Quarterly Earnings on Monday - MarketBeat
Is AnaptysBio Inc. stock overvalued or undervaluedBuild wealth faster with disciplined trading - jammulinksnews.com
Order flow analysis tools used on AnaptysBio Inc. Sector-Wise Stock Strength Trend Analysis - Newser
JPMorgan Chase & Co. Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $80.00 - MarketBeat
How many analysts rate AnaptysBio Inc. as a “Buy”Chart Pattern Planner That Work - jammulinksnews.com
When is AnaptysBio Inc. stock expected to show significant growthAchieve consistent double-digit growth rates - jammulinksnews.com
Published on: 2025-07-27 22:00:06 - jammulinksnews.com
Is AnaptysBio Inc. stock a growth or value playSolid Return Trade Selections - Newser
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - Defense World
Is AnaptysBio Inc. a good long term investmentConsistently high yield - PrintWeekIndia
What drives AnaptysBio Inc. stock priceExceptional market performance - PrintWeekIndia
AnaptysBio Analyst Expectations: Bullish Sentiments, Increasing Price Targets - AInvest
Does AnaptysBio Inc. stock pay reliable dividendsOutstanding trading profits - jammulinksnews.com
Trading (ANAB) With Integrated Risk Controls - news.stocktradersdaily.com
AnaptysBio Inc. Stock Analysis and ForecastConsistent triple-digit returns - jammulinksnews.com
What analysts say about AnaptysBio Inc. stockHigh-yield portfolio picks - jammulinksnews.com
How AnaptysBio Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):